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Abstract
No strategies for the diagnosis and treatment of biliary tract 
carcinoma have been clearly described. We developed ﬂ  ow-
charts for the diagnosis and treatment of biliary tract carci-
noma on the basis of the best clinical evidence. Risk factors 
for bile duct carcinoma are a dilated type of pancreaticobiliary 
maljunction (PBM) and primary sclerosing cholangitis. A 
nondilated type of PBM is a risk factor for gallbladder carci-
noma. Symptoms that may indicate biliary tract carcinoma are 
jaundice and pain in the upper right area of the abdomen. The 
ﬁ  rst step of diagnosis is to carry out blood biochemistry tests 
and ultrasonography (US) of the abdomen. The second step 
of diagnosis is to ﬁ  nd the local extension of the carcinoma by 
means of computed tomography (CT), magnetic resonance 
imaging (MRI), magnetic resonance cholangiopancreatogra-
phy (MRCP), percutaneous transhepatic cholangiography 
(PTC), and endoscopic retrograde cholangiopancreatography 
(ERCP). Because resection is the only way to completely cure 
biliary tract carcinoma, the indications for resection are deter-
mined ﬁ  rst. In patients with resectable disease, the indications 
for biliary drainage or portal vein embolization (PVE) are 
checked. In those with nonresectable disease, biliary stenting, 
chemotherapy, radiotherapy, and/or best supportive care is 
selected.
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Introduction
There have been no reports of a comprehensive clinical 
system to cover all entities of bile duct carcinoma, gall-
bladder carcinoma, and ampullary carcinoma. In addi-
tion, there is no clear consensus as to the best methods 
of diagnosis and treatment of biliary tract carcinoma. 
We therefore developed ﬂ  owcharts for the diagnosis 
and treatment of biliary tract carcinoma, on the basis 
of the best clinical evidence provided until 2007. Six 
levels of evidence were used (see deﬁ  nitions of levels 
in Table 1
1), and the levels are noted here in parenthe-
ses after the citations of relevant references. The ﬂ  ow-
chart for diagnosis consists of: (1) risk factors, (2) 
clinical presentation, (3) the ﬁ  rst step of diagnosis, and 
(4) the second step of diagnosis. The ﬂ  owchart for treat-
ment consists of: (1) resectable cases and (2) nonresect-
able cases.
Flowchart for the diagnosis of biliary tract carcinoma
The ﬂ  owchart for the diagnosis of biliary tract carci-
noma is shown in Fig. 1.
Risk factors
Risk factors for bile duct carcinoma are a dilated type 
of pancreaticobiliary maljunction (PBM) and primary 
sclerosing cholangitis. Biliary tract carcinoma occurred 
in 10.6% of patients with a dilated type of PBM, and 
bile duct carcinoma occurred in 33.6% of such pa-
tients
2 (level IV). Bile duct carcinoma occurred in 5%–
10% of patients with primary sclerosing cholangitis
3–6 
(level V).
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Fig. 1.  Flowchart for the diagnosis of biliary tract and ampul-
lary carcinomas. US, Ultrasonography; CT, computed tomog-
raphy; MRI, magnetic resonance imaging; MRCP, magnetic 
resonance cholangiopancreatography; ERC, endoscopic retro-
grade cholangiography; PTC, percutaneous transhepatic 
cholangiography;  EUS, endoscopic ultrasonography; PTCS, 
percutaneous transhepatic cholangioscopy; POCS, peroral 
cholangioscopy
A nondilated type of PBM is a risk factor for gallblad-
der carcinoma. Biliary tract carcinoma occurred in 
37.9% of patients with a nondilated type of PBM, while 
gallbladder carcinoma occurred in 93.2% of such 
patients
2 (level IV).
No risk factor is known for ampullary carcinoma.
Clinical presentation
Symptoms that may indicate biliary tract carcinoma are 
jaundice and pain in the upper right area of the 
abdomen.
For 90% of patients with bile duct carcinoma, the 
presenting symptom was jaundice
7,8  (level IV). In 
patients without jaundice, the presenting symptom was 
pain in the abdomen, fever, anorexia, or lassitude
2,7–9 
(level IV).
The symptom most often seen in gallbladder carci-
noma is pain in the upper right area of the abdomen
10,11 
(level IV). Other signs and symptoms are nausea, vomit-
ing, loss of weight, jaundice, anorexia, a feeling of abdom-
inal distension, pruritus, and black feces
10 (level IV).
Symptoms of ampullary carcinoma in many patients 
are jaundice, fever, and abdominal pain
12,13 (level IV).
Table 1.  Levels of evidence
1
Level I Systematic review/meta-analysis
Level II One or more randomized clinical trials
Level III Nonrandomized controlled trials
Level IV Analytic epidemiology (cohort studies and case-control studies)
Level V Descriptive study (case reports and case-series studies)
Level VI Opinions of expert panels and individual experts not based on 
patient’s dataS. Miyakawa et al.: Flowcharts for the management of biliary cancer  9
First step of diagnosis
The ﬁ  rst step of diagnosis is to carry out blood biochem-
istry tests and ultrasonography (US) of the abdomen. 
In blood biochemistry tests in patients with bile 
duct obstruction, rises in hepatobiliary enzymes are 
observed
14,15 (level III). Carbohydrate antigen (CA) 19-
9 is elevated in 50%–79% of patients with biliary tract 
carcinoma
16–19 (levels II and III), and carcinoembryonic 
antigen (CEA) is elevated in 40%–70% of such 
patients
19–21 (level III).
If there is a suspicion of biliary tract carcinoma, US 
is the ﬁ  rst diagnostic imaging to be applied. If dilation 
of the bile duct is found, it is possible to identify the 
obstructed region
14,15 (level III). For gallbladder carci-
noma, the tumor is identiﬁ  ed by US in more than 50% 
of patients
14 (level III).
Second step of diagnosis
Bile duct carcinoma
Computed tomography (CT) and magnetic resonance 
imaging (MRI; including magnetic resonance cholangi-
opancreatography [MRCP]) are useful to check on the 
location of bile duct carcinoma or to ﬁ  nd the local 
extension of such carcinoma. Contrast-enhanced CT is 
useful for ﬁ  nding the main local extension of cancer. In 
addition, examining whether there is invasion of the 
cancer into blood vessels by means of contrast-enhanced 
CT is important for deciding how to treat the cancer
22–24 
(level II-IV). In bile duct carcinoma without thickening 
of biliary walls, it is difﬁ  cult to identify local extension 
or depth only by means of CT
22,23 (levels II and IV).
MRCP is useful for identifying the obstructed region 
in the bile duct, for ﬁ  nding the local extension of the 
carcinoma, and for checking on PBM
25 (level IV). MRCP 
has a sensitivity of 70%–96% in determining whether a 
bile duct stricture is of benign/malignant nature, and is 
able to identify obstructed regions with a sensitivity of 
94%–99%
26–28 (levels III and IV).
Endoscopic retrograde cholangiopancreatography 
(ERCP) and percutaneous transhepatic cholangiogra-
phy (PTC) are useful for examining the horizontal inva-
sion of nodular bile duct carcinoma, and for indicating 
nodular and invasive bile duct carcinoma
29,30  (level 
IV).
Examination of cells or tissues is carried out as 
required. The positive rate of bile cytology determined 
by means of endoscopic retrograde cholangiography 
(ERC) is about 30%
25 (level II). A combination of brush 
cytology and biopsy of the bile duct increases the posi-
tive rate to 40%–70%
25 (level II).
Percutaneous transhepatic cholangioscopy 
(PTCS)
31–33  and peroral cholangioscopy (POCS)
34,35 
enable close examination of the lumen of the bile duct. 
These modalities are useful in both differentiating 
benign and malignant biliary strictures and in diagnos-
ing the superﬁ  cial mucosal spread of bile duct carci-
noma along the bile duct wall.
Gallbladder carcinoma
In the diagnosis of gallbladder carcinoma, differential 
diagnosis and determination of the local extension of 
tumor are important. For these purposes, imaging 
modalities such as endoscopic ultrasonography (EUS), 
CT, MRI, and MRCP are useful. EUS has good sensitiv-
ity, of 92%–97%, in differentiating benign gallbladder 
diseases from gallbladder carcinoma
36–38 (level IV). CT 
has a capability of diagnosis of tumorous lesions in the 
gallbladder with a sensitivity of 88%, a speciﬁ  city of 
87%, and a correct diagnosis rate of 87%
39 (level IV). 
In a report that evaluated the diagnosis of the resect-
ability of gallbladder carcinoma, accuracy of the diag-
nosis of resectability with CT was 93.3%
40 (level IV). 
According to some reports, in the diagnosis of direct 
invasion of tumor into the liver, MRI combined with 
MRCP had a sensitivity of 67%–100% and a speciﬁ  city 
of 89%; in the diagnosis of invasion of tumor into the 
bile duct, it had a sensitivity of 62%–100% and a speci-
ﬁ  city of 89%; and in the diagnosis of cancer metastasis 
to lymph nodes, it had a sensitivity of 56%–92% and a 
speciﬁ  city of 89%
41,42 (level IV).
Ampullary carcinoma
For the examination of ampullary carcinoma, endo-
scopic biopsy is used. For the examination of distant 
metastasis of cancer, e.g., to the liver, US, CT, and MRI 
are used. For the examination of invasion to the pan-
creas or the duodenum, EUS or intraductal ultrasonog-
raphy (IDUS) is useful
43,44 (level II).
Flowchart for the treatment of biliary tract carcinoma
The ﬂ  owchart for the treatment of biliary tract carci-
noma is shown in Fig. 2.
Indications for resection
Resection is the only radical treatment for biliary tract 
carcinoma. Its possibility should, therefore, be consid-
ered ﬁ  rst. If such cancer involves metastasis to the liver, 
the lung or the peritoneum, it is not resectable
45–47 (level 
IV). On the other hand, there is a report which advo-
cates surgery for patients with paraaoric lymph node 
metastasis, because the outcome is expected to be 
improved by surgery
48,49 (level IV). However, there is no 
consensus on standards for local extension factors or on 
the level of metastasis of lymph nodes that would deter-
mine whether the cancer is nonresectable.10  S. Miyakawa et al.: Flowcharts for the management of biliary cancer
Resectable cancers
Preoperative management
Biliary drainage. Many reports suggest that, except for 
patients with cholangitis or hepatic disorders, surgical 
operations that are as invasive as pancreatoduodenec-
tomy do not need preoperative biliary drainage
50–54 
(levels IV and VI). The mortality from complications in 
major hepatectomy is about 10%, and the main cause 
of death is hepatic failure
55 (level IV). In patients with 
severe jaundice, therefore, biliary drainage is carried out 
before surgical operation. For biliary drainage, it is, in 
principle, sufﬁ  cient to drain only the future remnant 
liver. However, there are no standards for indications 
for such drainage.
Portal vein embolization (PVE).  In patients who require 
right hemihepatectomy and more extended hepatec-
tomy, or 50%–60% hepatectomy, particularly patients 
with obstructive jaundice, PVE may be performed. It 
may reduce postoperative complications or deaths 
related to the operations
56–62 (levels III and IV).
Surgery
The results of surgical treatment of biliary tract carci-
noma have been improved with various new 
procedures.
Bile duct carcinoma.  For hilar cholangiocarcinoma and 
upper bile duct carcinoma, extrahepatic bile duct resec-
tion with hepatectomy is a standard surgical procedure; 
and for middle or lower bile duct carcinoma, pancreato-
duodenectomy is a standard procedure. For many 
patients with hilar cholangiocarcinoma, combined resec-
tion of the caudate lobe is recommended
63–65 (level IV); 
however, there is a report which describes that caudate 
lobe resection did not inﬂ  uence the outcome of patients 
with hilar cholangiocarcinoma
66. In patients with upper 
or middle bile duct carcinoma, resection of the extrahe-
Fig. 2.  Flowchart for the treatment of biliary tract and ampullary carcinomas. PVE, Portal vein embolizationS. Miyakawa et al.: Flowcharts for the management of biliary cancer  11
patic bile duct is indicated in those patients with papil-
lary lesions localized in such regions, without clear 
metastasis to lymph nodes
67–69 (level IV). In addition, it 
is preferable to conﬁ  rm a negative surgical margin 
in intraoperative rapid pathological examination. 
Combined resection of the portal vein in patients with 
tumor invasion into the portal vein resulted in a more 
satisfactory outcome than that seen in nonresectable 
patients
70–74 (level IV). So this combined resection may 
be performed.
Gallbladder carcinoma.  Gallbladder carcinoma involves 
various modes of extension to adjacent organs, such as 
invasion into the liver, hepatoduodenal ligament, duo-
denum, or transverse colon. So it is important to select 
the type of surgical operation according to the mode of 
extension on a case-by-case basis, aiming at no residual 
tumor
75,76 (level IV).
Ampullary carcinoma.  For this carcinoma, the standard 
operation is pancreatoduodenectomy. The indication 
for carcinoma in adenoma is  minimally invasive 
surgery
77–79 (level IV).
Adjuvant therapy
For chemotherapy, there are no recommendable regi-
mens, so such therapy is used on a trial basis. For radio-
therapy, some reports have stated that it was useful; 
however, there is no highly reliable evidence for stan-
dard therapy
80–83 (level IV). Accordingly, radiotherapy 
may be used in patients who have a positive surgical 
margin postoperatively
84  (level IV). However, one 
should be cautious in using radiotherapy in patients 
with curative resection.
Nonresectable cancers
Biliary drainage and stenting
For patients with lower bile duct obstruction, biliary 
stenting is carried out. The stenting is preferably by an 
endoscopic route
85,86 (level II). For the type of stent, a 
metal stent is recommended for patients with lower bile 
duct obstruction
87–92 (level II).
Chemotherapy, radiotherapy, and 
photodynamic therapy
Chemotherapy.  For patients in a good general state, 
chemotherapy is applied
93–96 (levels II and IV). No stan-
dard chemotherapy has yet been established. A combi-
nation therapy regimen with gemcitabine hydrochloride 
is now in a phase II study.
Radiotherapy.  It is reported that radiotherapy has a 
better effect in improving survival time than palliative 
therapy
97,98 (level IV). In addition, another advantage of 
radiotherapy is that the patency of the stent may be 
maintained and pain may be reduced by local control.
Photodynamic therapy. It is recognized that photody-
namic therapy combined with biliary stenting has a sig-
niﬁ  cantly better effect in improving survival time than 
biliary stenting only
99,100 (level II).
Best supportive care
For patients in whom chemotherapy and radiotherapy 
are not indicated due to a poor general state or persis-
tent jaundice, best supportive care, such as pain control, 
should be applied for the purpose of maintaining quality 
of life.
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